Quietly replacing the old way: customers are switching to the company from an entrenched alternative, and the switching
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes customers switching from an entrenched alternative to their product, and that this switching is still early with most potential switchers not yet converted. Let's scan the transcript for relevant statements. Key areas: - Prevnar: management discusses adult market in US where they have 96% market share, but the patient pool is decreasing. They mention competition from V116. They say the adult market is not expected to grow much because the catch-up opportunity is exhausted. Pediatric market is growing. This doesn't seem like switching from an entrenched alternative; it's more about market dynamics. - Abrysvo: They talk about increasing market share, but not specifically about switching from an incumbent. They mention retail contracting and differentiating with maternal indication. Not clearly a substitution story. - Nurtec: They talk about being number one prescribed CGRP, but not about switching from an entrenched alternative. They mention competition but not displacement. - Oxbryta: They talk about growth, but not about switching from an alternative. - Velsipity: They talk about it as an oral option for UC, but not about switching from an entrenched alternative. - GBT-601: They talk about it as next-generation, but not about switching. - Oncology: They talk about PADCEV and XTANDI launches, but not about switching from an incumbent. - The overall theme is about execution and growth, but not specifically about customers switching from an entrenched alternative. Look for phrases like "displacing", "switching", "replacing", "moving off", "converting", "abandoning", "incumbent", "legacy", "old way", etc. In the transcript, there is a mention of "switching" in the context of Velsipity? Actually, they say "patients that haven't progressed to an advanced therapy prefer an oral option" but that's about patients not yet on advanced therapy, not switching from an entrenched alternative. There is a mention of "co-administration with flu vaccines" but that's not switching. The question asks: "customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON" and "this switching is still in its early stages, with most of the potential switchers not yet converted." I don't see any clear statement from management that describes such a phenomenon.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| BIG | Big Lots, Inc. | Q1 2022 | 2022-05-27 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
BLKB · Q1 2017 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES Management describes customers switching from entrenched alternatives (legacy hardware systems, older Raiser's Edge versions, standalone point solutions) to Blackbaud's cloud solutions like NXT, with examples of recent replacements and migrations already occurring. They also note that much of the potential remains, as the installed base of legacy methods is still large 25% of subscription revenue, and they describe the opportunity as "really early days" with substantial distance left to run. This fits the criteria of a present-tense substitution pattern in the market, not just future hope. The high retention on their own base (93%) combined with declining maintenance revenue shows the shift is active and ongoing, while new wins against competitors and legacy alternatives are happening now. The TAM of $7 billion with hundreds of thousands of addressable customers reinforces that switching is early-stage relative to the total opportunity. The answer is YES. The question is answered with YES. The question is answered with YES.
BLZE · Q3 2022 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing current customer switches from entrenched alternatives (AWS for urlscan.io; Synology NAS/on-prem for Fiture; broader AWS and on-prem users), with these as real, ongoing patterns. They explicitly note that much of the potential remains ("so much of the world's data is still on-premises" and "customers that are inside of AWS and others"), confirming the substitution is early-stage relative to the large installed base. This is conveyed directly in Gleb's responses as a present-tense reality, not merely anticipated. The two examples plus the broader opportunity framing establish a coherent substitution underway, with the company being substituted in. The investor question on percentages and Gleb's reply reinforce the pattern without contradicting the current movement. No single-event or future-only framing applies here. Thus, both conditions are met.
APPS · Q1 2024 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing customers shifting from Apple/Google app stores to DT Hub and SingleTap-enabled alternative distribution as an ongoing, early-stage substitution. Bill Stone notes the company has already launched DT Hub with four U.S. operators and is generating revenue today, while highlighting "increasing pressure on the duopoly" and 5 monetization ways for SingleTap that enable publishers to direct-download apps outside traditional stores. He explicitly calls it "very early days and not yet material to our overall results" and "early innings," confirming the installed base of the old way remains large and the switch is just beginning with incremental RPD gains from devices engaging the new platform. This meets the criteria of a present-tense substitution underway, with the company positioned as the alternative being adopted.